Markel launches Clinical Trials products to support clinical trials research, globally
Rhea-AI Summary
Markel Insurance (NYSE: MKL) has launched a new Clinical Trials insurance product designed to provide comprehensive coverage for sponsors, researchers, and participants across all phases of clinical research. The product offers coverage in over 100 territories and features same-day quotation turnaround along with automated document production for certificates and policies.
Key features include Lloyd's licenses utilization, an extensive global network for compliant solutions, and expert underwriting backed by award-winning claims service. The offering aims to streamline the insurance process, which is often the final regulatory requirement before clinical trials can begin, helping avoid costly delays and research suspensions.
Positive
- Launch of new comprehensive Clinical Trials insurance product covering over 100 territories
- Same-day turnaround for quotations and automated document processing
- Potential for new revenue stream in the growing clinical trials sector
- Leveraging existing Lloyd's licenses and global network for expanded market reach
Negative
- None.
News Market Reaction – MKL
In the trading session that priced this news, MKL gained 0.16%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The new clinical trials offering provides comprehensive cover to sponsors, researchers and participants throughout all phases of clinical research and is tailored to meet the regulatory requirements of more than 100 territories, ensuring smooth and compliant trial operations, worldwide.
As part of its service offering, Markel can offer same-day turnaround for quotations, as well as the issuance of certificates and policy documents through its automated document production platform, so that clinical trial sponsors and researchers can get the required insurance in place to begin clinical trials in a timely manner and meet regulatory deadlines. Markel utilises its Lloyd's licenses and extensive global network to provide these solutions to ensure a compliant solution where required.
"Clinical trials insurance is a regulatory requirement in many countries and it's often the last hurdle to get approval to begin clinical research," says Robert Hannaford, Senior Underwriter – Life Science, Markel. "Delays to this process can result in sizeable costs, reputational damage and suspend vital research from going ahead for sponsors and researchers.
"At Markel, we understand the time-sensitive nature of these requests and have developed a compliant solution – backed by our expert underwriting and award-winning claims service, making sure clients are fully protected to carry out the clinical research of products worldwide."
Hannaford continues: "We do not want insurance to be a delaying factor to allowing important clinical research to begin, which is why we've produced a customer-centric product that streamlines all parts of the insurance value chain to prioritise service.
"We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer solutions for future lifesaving treatments through open communication, dialogue and transparency with our brokers, insureds and trading partners."
About Markel Insurance
We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/markel-launches-clinical-trials-products-to-support-clinical-trials-research-globally-302445849.html
SOURCE Markel